ADMA Biologics Faces Securities Fraud Investigation Over Alleged Channel Stuffing

BFA Law Notifies Investors to Contact Firm Regarding Potential Class Action Lawsuit

Apr. 10, 2026 at 10:20am

Got story updates? Submit your updates here. ›

A minimalist studio still life photograph featuring a stack of financial documents, a calculator, and a gavel floating on a clean white background, conceptually representing an investigation into corporate fraud and securities violations.An investigation into alleged financial misconduct at ADMA Biologics raises concerns about transparency and accountability in the pharmaceutical industry.NYC Today

Leading securities law firm Bleichmar Fonti & Auld LLP has launched an investigation into ADMA Biologics, Inc. for potential violations of federal securities laws. The investigation focuses on allegations that ADMA Biologics engaged in a channel stuffing scheme to artificially inflate its reported 20% revenue growth in 2025, when the company's actual growth was a 3% decline.

Why it matters

The allegations of channel stuffing, if proven true, could have significant implications for ADMA Biologics and its investors. Channel stuffing is a form of accounting fraud that can mislead investors about a company's true financial performance. This investigation highlights the importance of transparency and accurate financial reporting in the biopharmaceutical industry.

The details

According to the investigation, ADMA Biologics allegedly induced one of its distributors to 'stock excess ASCENIV by offering rebates and extended payment terms' in order to meet revenue expectations and report 20% growth in 2025. However, the investigative research firm Culper Research claims that without this alleged channel stuffing scheme, ADMA Biologics would have actually experienced a 3% revenue decline that year.

  • On March 24, 2026, Culper Research published a report detailing the alleged channel stuffing scheme.
  • On March 25, 2026, ADMA Biologics' stock price dropped 29% in response to the Culper Research report.

The players

ADMA Biologics, Inc.

An end-to-end commercial biopharmaceutical company focused on manufacturing and developing specialty biologics, including its flagship product ASCENIV, a liquid immune globulin solution.

Bleichmar Fonti & Auld LLP

A leading international law firm representing plaintiffs in securities class actions and shareholder litigation, which has launched an investigation into ADMA Biologics for potential securities fraud.

Culper Research

An investigative research firm that published a report alleging ADMA Biologics engaged in a channel stuffing scheme to artificially inflate its 2025 revenue growth.

Got photos? Submit your photos here. ›

What they’re saying

“If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.”

— Bleichmar Fonti & Auld LLP, Law Firm

What’s next

BFA Law is encouraging ADMA Biologics investors to contact the firm to potentially participate in a class action lawsuit regarding the alleged securities fraud.

The takeaway

This investigation highlights the importance of transparency and accurate financial reporting in the biopharmaceutical industry, as allegations of channel stuffing can have significant implications for a company and its investors.